Arbutus Biopharma Corporation ABUS
As ofNov 20, 2026, 2:39 PM EST
- YTD
- -15.38%
- 1 year
- -3.10%
Fundamental scorecard
15 of 25 checks passed on ABUS’s reported financials
15of 25 checks passed
- Value 3 of 5
- Growth 3 of 5
- Profitability 4 of 5
- Financial health 5 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Value 3 of 5
- No data:P/E below its own 5-year median P/E 2.8. Not enough data to decide.
- Passed:P/E under 20 P/E 2.8: an earnings yield of 35.3%.
- Passed:Price to sales below its own 5-year median Price to sales 3.4 against a 5-year median of 47.9.
- Failed:Price to book below its own 5-year median Price to book 7.3 against a 5-year median of 4.0.
- Passed:Free cash flow yield above 4% Free cash flow of 221M is 35.5% of the market value.
Growth 3 of 5
- Passed:Revenue grew over the last year Revenue of 181M is +1142.6% on the 12 months before.
- Passed:Revenue grew more than 5% a year over five years +15.3% a year from FY 2020 to FY 2025.
- Passed:Earnings per share grew over the last year EPS 1.13 against -0.23 in the 12 months before.
- Failed:Earnings per share grew more than 5% a year over five years EPS -1.00 in FY 2020, -0.17 in FY 2025.
- Failed:Analysts expect higher earnings per share over the next year The average forward estimate is -120.9% on the last 12 months.
Profitability 4 of 5
- Passed:Profitable over the last year Net income of 220M over the last 12 months.
- Failed:Profitable in each of the last five fiscal years A profit in 0 of the last 5 fiscal years.
- Passed:Return on equity above 15% Return on equity of 269.6%.
- Passed:Net margin above its 5-year average Net margin of 121.2% against a 5-year average of -551.0%.
- Passed:Free cash flow is at least 80% of net income Free cash flow of 221M is 100.7% of net income.
Financial health 5 of 5
- Passed:Short-term assets cover short-term liabilities Short-term assets of 340M against short-term liabilities of 242M.
- Passed:Short-term assets cover long-term liabilities Short-term assets of 340M against long-term liabilities of 12.0M.
- Passed:Net debt under 40% of equity More cash than debt: 337M of cash against 3.31M of debt.
- Passed:Operating cash flow covers at least 20% of debt Operating cash flow of 221M is 6678.9% of debt.
- Passed:Operating profit covers interest at least 3 times Operating profit is 3437 times the interest expense.
Dividend 0 of 5
- Failed:Pays a dividend No dividend paid.
- Failed:Yield above 1.5% No dividend paid.
- Failed:Pays out under 75% of profit No dividend paid.
- Failed:Covered by free cash flow No dividend paid.
- Failed:Not cut in the last five fiscal years No dividend paid.
Mechanical checks on reported financials against fixed thresholds. They describe the numbers; they are not a recommendation to buy or sell.
Included in Essentials and up
Sign in to see Fair value
Discounted cash flow estimates against the price, and the P/E against its industry and sector.
Included in Essentials and up
Sign in to see Head count and owner earnings
Employees by annual report and the cash the business earns for its owners.
Included in Essentials and up
Sign in to see P/E against peers
The price to earnings ratio beside the closest competitors and their median.
Financial position
What ABUS owns and owes, as of Sep 30, 2026
Short term and long term
Balance sheet · 340M of assets
Debt, equity and cash by year
Now: 334M more cash than debt
Fiscal years, then the newest quarter. Cash includes short-term investments.
From the company’s SEC filings.
Included in Essentials and up
Sign in to see Cash flow and returns
How profit turns into free cash flow, and the returns on equity, assets and capital.
Financial health
Altman Z-Score
-0.28 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
7 / 9 Strong
Nine pass/fail tests of profitability, leverage and efficiency.
Rating
B+3 / 5 overall
- DCF 1
- Return on Equity 5
- Return on Assets 5
- Debt / Equity 4
- P/E 3
- P/B 1
